OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology International is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
The safety profile of endoscopic variceal ligation in patients with esophageal varices	116
HBV in pregnancy: time to consider tenofovir alafenamide (TAF)	98
Metabolically healthy obese and MAFLD: does weight status alone matter?	93
Platelets in acute liver failure: an innocent bystander or instigator?	79
Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network	73
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial	67
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk	60
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD	60
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression	58
‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure	54
Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies	53
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease	48
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India	42
Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria	42
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes	42
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis	41
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”	40
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis	40
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality	37
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study	36
Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies	36
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy	36
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis	36
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets	34
Effect of microbiota metabolites on the progression of chronic hepatitis B virus infection	34

Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma	33
Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis	32
Commentary on “Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled t	32
Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study	32
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection	32
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis	30